| 2026-03-09 | +48.4% | news | Seeking Alpha | Hims & Hers: Not Selling Yet |
| 2026-03-09 | +48.4% | expansion | Seeking Alpha | Hims & Hers Health boosted at Citi on Novo Nordisk partnership |
| 2026-03-09 | +48.4% | news | Seeking Alpha | Hims & Hers Health: The Juice Is Worth The Squeeze |
| 2026-03-09 | +48.4% | analyst | Seeking Alpha | Hims & Hers Short Squeeze Is Looking Dangerous (Rating Downgrade) |
| 2026-03-09 | +48.4% | news | Morningstar | Hims & Hers: Repartnering With Novo Removes Legal Overhang and Reshapes Weight Loss Segment - Morningstar |
| 2024-02-26 | +41.3% | legal | SEC EDGAR | HIMS 8-K: 2.02 and (SEC Filing) |
| 2025-06-23 | -35.2% | news | GlobeNewswire | BREAKING: Hims & Hers Health, Inc. Investigated For - GlobeNewswire |
| 2022-11-07 | +28.6% | legal | SEC EDGAR | HIMS 8-K: 2.02 and (SEC Filing) |
| 2025-02-20 | -26.2% | news | TradingView | Recent Insider Transactions at Hims & Hers Health - TradingView |
| 2026-02-09 | -25.3% | news | Seeking Alpha | Hims & Hers Health: The Company Will Survive, But Investors Should Expect A 'Washout' - Seeking Alpha |
| 2026-04-15 | +25.3% | legal | Seeking Alpha | FDA sets up AdCom meeting to decide on lifting restrictions on certain peptides |
| 2025-05-05 | +22.6% | legal | SEC EDGAR | HIMS 8-K: 2.02 and (SEC Filing) |
| 2025-05-05 | +22.6% | news | HIMS Investor Relations | Hims Inc. - Hims & Hers Health, Inc. Reports First Quarter 2025 Financial Results - HIMS Investor Relations |
| 2025-05-05 | +22.6% | news | CNBC | Hims & Hers gives weak outlook but says more collaborations are coming - CNBC |
| 2025-02-24 | -18.2% | legal | SEC EDGAR | HIMS 8-K: 2.02 and (SEC Filing) |
| 2025-06-26 | +18.0% | expansion | Yahoo Finance | Hims & Hers Health (NYSE:HIMS) Faces Class Action After Partnership Termination With Novo Nordisk - Yahoo Finance |
| 2026-04-16 | +17.2% | news | Seeking Alpha | Biggest stock movers Thursday: AEHR, ABT, HOOD, COIN, and more |
| 2026-04-16 | +17.2% | analyst | Seeking Alpha | FDA Peptide Review, A Big Moment For Hims & Hers (Rating Upgrade) |
| 2026-04-16 | +17.2% | news | Seeking Alpha | Hims & Hers on track to extend gains as RFK Jr. seeks to loosen peptide regulations |
| 2026-03-10 | +17.1% | news | Seeking Alpha | Hims & Hers Health: The GLP-1 Chaos Is Fading, The Thesis Is Still On Track |
| 2024-07-22 | +16.4% | legal | SEC EDGAR | HIMS 8-K: 5.02 (SEC Filing) |
| 2024-11-21 | +15.4% | legal | SEC EDGAR | HIMS 8-K: 5.02 (SEC Filing) |
| 2023-02-27 | +15.4% | legal | SEC EDGAR | HIMS 8-K: 2.02 and (SEC Filing) |
| 2021-05-17 | +14.8% | legal | SEC EDGAR | HIMS 8-K: 2.02 (SEC Filing) |
| 2025-09-18 | +14.2% | news | StocksToTrade | Hims & Hers Health Inc. Class A (HIMS) Stock Price | Live Quotes & Charts | NYSE - StocksToTrade |
| 2026-04-17 | +13.9% | analyst | Seeking Alpha | SA analyst upgrades/downgrades: NVDA, VZ, MRVL, HIMS |
| 2026-04-17 | +13.9% | news | Seeking Alpha | GLP-1 trials show mood improvement rather than the Ozempic personality – Dr. Angela Fitch |
| 2026-04-17 | +13.9% | news | Morningstar | Weekly Market Update: Stocks Gain 4.62% to Hit New All-Time High as Tech Rises, Energy Falls - Morningstar |
| 2026-04-14 | +12.8% | news | Seeking Alpha | Hims & Hers: Bargain EBITDA Multiples As GLP-1 Drama Passes |
| 2025-08-04 | -12.2% | legal | SEC EDGAR | HIMS 8-K: 2.02, 8.01 (SEC Filing) |
| 2025-07-29 | +12.1% | news | Investing.com | Soleil Boughton, Hims & Hers health CLO, sells $150k in stock - Investing.com |
| 2023-05-08 | -11.1% | legal | SEC EDGAR | HIMS 8-K: 2.02 and (SEC Filing) |
| 2022-02-22 | +10.8% | legal | SEC EDGAR | HIMS 8-K: 2.02 and (SEC Filing) |
| 2021-11-18 | -10.1% | legal | SEC EDGAR | HIMS 8-K: 5.02 (SEC Filing) |
| 2022-05-09 | -10.1% | legal | SEC EDGAR | HIMS 8-K: 2.02 and (SEC Filing) |
| 2025-05-13 | +9.9% | legal | SEC EDGAR | HIMS 8-K: 1.01, 2.03, 3.02 (SEC Filing) |
| 2025-05-13 | +9.9% | news | Investing.com | Hims & Hers Health Inc. issues $1B in convertible notes - Investing.com |
| 2023-08-07 | -9.1% | legal | SEC EDGAR | HIMS 8-K: 2.02 and (SEC Filing) |
| 2024-05-06 | +8.5% | legal | SEC EDGAR | HIMS 8-K: 2.02 and (SEC Filing) |
| 2026-03-27 | -7.9% | news | Seeking Alpha | Hims & Hers: The Reset Before The Next Inflection |
| 2026-03-27 | -7.9% | news | Stock Titan | Vanguard (HIMS) reports 0 shares after internal realignment — Schedule 13G/A - Stock Titan |
| 2024-10-03 | -7.5% | news | timothysykes.com | Will Hims & Hers Health Inc. Class A Stock Continue to Rise or Lose its Momentum? - timothysykes.com |
| 2026-03-24 | -7.4% | executive | Investing.com | Okupe, Hims & Hers health CFO, sells $219k in shares - Investing.com |
| 2026-03-24 | -7.4% | news | Stock Titan | [Form 4] Hims & Hers Health, Inc. Insider Trading Activity - Stock Titan |
| 2026-04-07 | -7.2% | earnings | Seeking Alpha | Healthcare quant check: RLAY and TNGX lead Seeking Alphas top picks ahead of Q1 earnings |
| 2026-04-07 | -7.2% | executive | Investing.com | Okupe, Hims & Hers health CFO, sells $79k in shares - Investing.com |
| 2025-04-21 | -7.1% | legal | SEC EDGAR | HIMS 8-K: 5.02 (SEC Filing) |
| 2023-11-06 | +7.0% | legal | SEC EDGAR | HIMS 8-K: 2.02 and (SEC Filing) |
| 2025-06-25 | +6.9% | news | GlobeNewswire | SHAREHOLDER ALERT: Hims & Hers Health, Inc. Sued For - GlobeNewswire |
| 2025-10-02 | -6.8% | legal | SEC EDGAR | HIMS 8-K: 5.02 (SEC Filing) |
| 2021-08-11 | +6.5% | legal | SEC EDGAR | HIMS 8-K: 2.02 and (SEC Filing) |
| 2021-11-10 | -6.2% | legal | SEC EDGAR | HIMS 8-K: 2.02 and (SEC Filing) |
| 2026-04-10 | +6.2% | executive | Stock Titan | Hims & Hers (NYSE: HIMS) CEO makes 845,866-share bona fide gift - Stock Titan |
| 2026-04-22 | -6.0% | news | Seeking Alpha | Hims & Hers doubles down on estrogen patches as demand surges |
| 2026-04-22 | -6.0% | executive | Investing.com | Hims & Hers CFO Oluyemi Okupe sells $588,615 in Hims stock - Investing.com |
| 2026-04-22 | -6.0% | executive | Stock Titan | Hims & Hers (HIMS) legal chief sells 9,463 shares in planned trade - Stock Titan |
| 2026-04-22 | -6.0% | executive | Investing.com | Hims & Hers chief legal officer Soleil Boughton sells $283,890 in stock - Investing.com |
| 2026-04-22 | -6.0% | executive | Stock Titan | Hims & Hers (NYSE: HIMS) CFO option exercises and pre-planned share sale - Stock Titan |
| 2026-04-03 | +5.7% | news | Seeking Alpha | Hims & Hers' Valuations Back To Earth - Robust Monetization Trends Deserve Reiterated Buy |
| 2026-04-03 | +5.7% | news | Seeking Alpha | Most and least shorted mid-to mega-cap healthcare stocks in March |
| 2023-02-23 | +5.7% | legal | SEC EDGAR | HIMS 8-K: 5.02 (SEC Filing) |
| 2025-09-30 | -5.5% | news | Trefis | Wait For A Dip To Buy Hims & Hers Health Stock - Trefis |
| 2025-07-08 | +5.3% | news | GlobeNewswire | HIMS NOTICE: Hims & Hers Health, Inc. Shareholders are - GlobeNewswire |
| 2022-02-04 | +5.0% | legal | SEC EDGAR | HIMS 8-K: 8.01 and (SEC Filing) |
| 2026-04-23 | +5.0% | legal | TheStreet | Hims stock price reacts strongly to crucial FDA review |
| 2026-04-23 | +5.0% | news | Investor's Business Daily | Hims & Hers Reverses Amid Doubts On Its Newest Obesity Plan |
| 2026-04-23 | +5.0% | executive | Koran Manado | Hims & Hers Health Legal Chief Sells Shares Worth Over $280000 - Koran Manado |
| 2024-09-09 | +4.9% | legal | SEC EDGAR | HIMS 8-K: 8.01 and (SEC Filing) |
| 2025-11-03 | -4.9% | legal | SEC EDGAR | HIMS 8-K: 2.02 and (SEC Filing) |
| 2025-08-12 | -4.7% | executive | MarketWatch | Hims & Hers CEO sells $33 million in stock after a massive rally - MarketWatch |
| 2021-09-07 | +4.4% | legal | SEC EDGAR | HIMS 8-K: 5.02, 7.01 (SEC Filing) |
| 2024-06-06 | -4.3% | legal | SEC EDGAR | HIMS 8-K: 5.02 (SEC Filing) |
| 2025-05-09 | +4.2% | legal | SEC EDGAR | HIMS 8-K: 8.01 and (SEC Filing) |
| 2026-04-20 | +4.1% | news | Stock Titan | HIMS (HIMS) insider sale notice: 4,651 and 4,812 Class A shares listed - Stock Titan |
| 2026-04-20 | +4.1% | executive | Investing.com | Hims & Hers CFO Okupe Oluyemi sells $1.46 million in company stock - Investing.com |
| 2026-04-20 | +4.1% | executive | Stock Titan | Hims & Hers (HIMS) CFO sells 54,927 shares under 10b5-1 plan - Stock Titan |
| 2026-03-26 | -3.5% | news | Seeking Alpha | Hims & Hers Health starts selling Novo Nordisk's Wegovy, Ozempic |
| 2025-09-05 | +3.2% | legal | SEC EDGAR | HIMS 8-K: 1.01 and (SEC Filing) |
| 2026-03-11 | +3.2% | M&A | Seeking Alpha | Hims & Hers: The Novo Nordisk Deal Changes Everything |
| 2026-03-11 | +3.2% | expansion | Seeking Alpha | This Novo Nordisk Partnership Shows That Hims & Hers Health Has All The Leverage |
| 2026-03-11 | +3.2% | executive | Seeking Alpha | Hims & Hers hires former Lilly communications chief |
| 2025-08-24 | -3.1% | legal | GlobeNewswire | Hims & Hers (HIMS) Stock Lawsuits: Investors Urged to Act - - GlobeNewswire |
| 2025-09-22 | -3.1% | legal | SEC EDGAR | HIMS 8-K: 8.01 (SEC Filing) |
| 2025-08-19 | -3.0% | news | TradingView | Why Hims & Hers Health (HIMS) Stock Is Falling Today - TradingView |
| 2022-08-08 | -2.8% | legal | SEC EDGAR | HIMS 8-K: 2.02 and (SEC Filing) |
| 2025-08-08 | -2.7% | earnings | GlobeNewswire | HIMS Shares Decline Amid Lower Revenue Per Order For GLP-1 - GlobeNewswire |
| 2025-06-24 | -2.5% | legal | GlobeNewswire | HIMS INVESTIGATION NOTICE: Hims & Hers Health, Inc. is - GlobeNewswire |
| 2025-04-24 | +2.3% | news | Stock Titan | Hims & Hers Health Stock Price, News & Analysis - Stock Titan |
| 2026-03-12 | -2.2% | earnings | Seeking Alpha | Hims & Hers Health And Novo Nordisk: A Corporate Remarriage That May Work Out Profitably |
| 2025-07-03 | +2.0% | news | GlobeNewswire | Robbins LLP Urges HIMS Stockholders with Large Losses to - GlobeNewswire |
| 2025-09-19 | +2.0% | news | TradingView | Hims & Hers Health Executives Conduct Series of Stock Transactions - TradingView |
| 2024-08-05 | -2.0% | legal | SEC EDGAR | HIMS 8-K: 2.02 and (SEC Filing) |
| 2026-03-31 | +2.0% | news | Seeking Alpha | Novo to sell Wegovy subscriptions on Hims, LifeMD, and others |
| 2026-04-08 | -1.9% | news | Seeking Alpha | Hims & Hers Health Is No Longer What The Market Thinks |
| 2025-10-22 | -1.8% | expansion | Sahm | Should You Rethink Hims After Volatile Moves and New Product Launches in 2025? - Sahm |
| 2025-07-27 | +1.8% | news | TMX Newsfile | HIMS STOCK REMINDER: BFA Law Reminds Hims & Hers Health, Inc. Investors with Losses to Contact the Firm by August 25 Legal Deadline - TMX Newsfile |
| 2022-01-20 | +1.8% | legal | SEC EDGAR | HIMS 8-K: 5.02 (SEC Filing) |
| 2026-02-19 | -1.8% | legal | SEC EDGAR | HIMS 8-K: 1.01, 3.02, 7.01 (SEC Filing) |
| 2026-02-19 | -1.8% | M&A | Stock Titan | Hims & Hers (NYSE: HIMS) plans $1.15B Eucalyptus deal for global growth - Stock Titan |
| 2025-07-04 | +1.7% | news | GlobeNewswire | HIMS SHAREHOLDERS: The Hims & Hers Health, Inc. August 25 - GlobeNewswire |
| 2026-03-18 | -1.6% | news | Seeking Alpha | UnitedHealth, Hims & Hers, Gambling.Com - Value Investing With Raul Shah |
| 2026-01-21 | -1.5% | executive | Investing.com | Okupe, CFO of Hims & Hers, sells $275k in HIMS stock - Investing.com |
| 2025-05-08 | -1.3% | news | HIMS Investor Relations | Hers Health, Inc. Prices Upsized $870.0 Million Convertible Senior Notes Offering to Accelerate Global Expansion and Utilization of AI in Healthcare - HIMS Investor Relations |
| 2025-05-08 | -1.3% | news | HIMS Investor Relations | Hers Health, Inc. Announces Proposed Convertible Senior Notes Offering to Accelerate Global Expansion and Utilization of AI in Healthcare - HIMS Investor Relations |
| 2025-07-24 | -1.1% | news | GlobeNewswire | HIMS STOCK NEWS: Hims & Hers Health, Inc. (NYSE:HIMS) is - GlobeNewswire |
| 2023-09-03 | +1.0% | news | StockInvest.us | HIMS - Hims & Hers Health Inc - Class A Company Profile - StockInvest.us |
| 2026-03-25 | -1.0% | news | Seeking Alpha | Hims & Hers: Distressed Valuations Will Not Last For Long |
| 2021-07-09 | +1.0% | legal | SEC EDGAR | HIMS 8-K: 8.01 and (SEC Filing) |
| 2024-04-26 | +1.0% | legal | SEC EDGAR | HIMS 8-K: 5.02 (SEC Filing) |
| 2024-04-03 | -1.0% | legal | SEC EDGAR | HIMS 8-K: 5.02 (SEC Filing) |
| 2025-07-21 | -0.9% | news | Stock Titan | Form 144 shows Hims & Hers insider to offload 125k shares - Stock Titan |
| 2023-09-06 | -0.9% | earnings | HIMS Investor Relations | Financials - Quarterly results - HIMS Investor Relations |
| 2021-05-04 | -0.9% | legal | SEC EDGAR | HIMS 8-K: 2.02, 4.02, 7.01 (SEC Filing) |
| 2026-02-23 | -0.8% | legal | SEC EDGAR | HIMS 8-K: 2.02 and (SEC Filing) |
| 2026-03-14 | -0.6% | M&A | Seeking Alpha | Hims & Hers posts best weekly gain after Novo deal |
| 2026-03-14 | -0.6% | earnings | Seeking Alpha | Mid-Cap healthcare stocks ranked by quant ratings after earnings season |
| 2026-02-24 | +0.4% | expansion | Morningstar | Hims & Hers Looks to Drive Growth Via International Expansion and New Therapy Launches - Morningstar |
| 2024-11-04 | +0.4% | legal | SEC EDGAR | HIMS 8-K: 2.02 and (SEC Filing) |
| 2021-08-05 | -0.3% | news | StockInvest.us | Historical HIMS stock prices (quote) - Hims & Hers Health Inc - Class A - StockInvest.us |
| 2025-10-31 | +0.2% | legal | Stock Titan | [SCHEDULE 13G] Hims & Hers Health, Inc. SEC Filing - Stock Titan |
| 2025-11-17 | -0.2% | legal | SEC EDGAR | HIMS 8-K: 8.01 (SEC Filing) |
| 2025-11-17 | -0.2% | news | HIMS Investor Relations | Hers Health, Inc. Announces $250 Million Share Repurchase Program Authorization - HIMS Investor Relations |
| 2025-11-17 | -0.2% | news | Investing.com | Hims & Hers Health board approves $250 million share repurchase program - Investing.com |
| 2025-11-17 | -0.2% | news | TradingView | Hims & Hers Health Announces New Share Repurchase Program - TradingView |
| 2026-04-26 | — | news | MSN | Hims & Hers Health effects new up to $250M stock buyback program, shares up ~2% - MSN |
| 2026-04-25 | — | expansion | Simply Wall St. | A Look At Hims & Hers Health (HIMS) Valuation After Fresh GLP-1 Analyst Endorsement And Pharma Partnerships |
| 2026-04-25 | — | news | StockStory | Why Is Hims & Hers Health (HIMS) Stock Soaring Today |
| 2026-04-25 | — | earnings | StockStory | 3 Market-Beating Stocks to Research Further |
| 2026-04-25 | — | M&A | Fathom Journal | HIMS Hims & Hers Health Inc: 5 Stock Signals After Novo Deal + Wednesday Predicted Opening Price? 📈 (g6weIcIV5G) - Fathom Journal |
| 2026-04-24 | — | earnings | Zacks | Tempus AI Nears Profitability as Operating Leverage Emerges |
| 2026-04-24 | — | M&A | 24/7 Wall St. | JPMorgan Initiates Hims & Hers With Overweight: Could the Novo Nordisk Deal Be the Turning Point? |
| 2026-04-24 | — | news | Simply Wall St. | How Expanding GLP‑1 Offerings and Partnering With LillyDirect At Hims & Hers Health (HIMS) Has Changed Its Investment Story |
| 2026-04-24 | — | analyst | The Fly | Intel upgraded, DraftKings downgraded: Wall Street's top analyst calls |
| 2026-04-24 | — | analyst | MT Newswires | JPMorgan Initiates Coverage on Hims & Hers Health With Overweight Rating, $35 Price Target |
| 2026-04-24 | — | news | Seeking Alpha | Hims rises as J.P. Morgan initiates at Overweight on rich catalyst path |
| 2026-04-24 | — | news | Seeking Alpha | Biggest stock movers Friday: MXL, INTC, COUR, CHTR, MXL, and more |
| 2026-04-24 | — | news | HIMS Investor Relations | Investor relations - HIMS Investor Relations |